You are here:

montelukast (Singulair)

Advice

Following a full submission

Montelukast (Singulair) is accepted for restricted use within NHS Scotland for the symptomatic relief of seasonal allergic rhinitis (SAR) in adult patients in whom montelukast is indicated in asthma, as add-on oral therapy at steps 3 and 4 of the BTS/SIGN asthma guidelines.

Other more effective and cost effective treatments for SAR are available for patients in whom montelukast is not required for the treatment of asthma.

Drug Details

Drug Name: montelukast (Singulair)
SMC Drug ID: 185/05
Manufacturer: MSD
Indication: Seasonal allergic rhinitis in adult patients in whom montelukast is indicated in asthma
BNF Category:
Sub Category: 3.3 Cromoglicate and related therapy and leukotriene receptor antagonists
Submission Type: Full submission
Status: Restricted
Date Advice Published: 11 July 2005

Back